Mandate

Vinge advises on equity line and rights issue guarantee to Karo Bio

October 27, 2010

Azimuth Opportunity, Inc and Karo Bio AB (publ) (NASDAQ OMX Stockholm) have entered an agreement regarding a so-called Equity Credit Facility, whereby Azimuth has undertaken to subscribe for new shares in Karo Bio on Karo Bio’s request and as set out in the terms of the facility, of up to USD 35 million. In addition, Azimuth guarantees part of Karo Bio’s rights issue of approx. SEK 300 million. The Facility and the rights issue are subject to approval by the general meeting of Karo Bio.

Vinge advises Azimuth. Vinge’s team is headed by capital markets partner Erik Sjöman.

Related

Vinge advises HealthCap in conjunction with an investment in Neobiomics

HealthCap is investing in Neobiomics AB, which develops products in the neonatal field. Neobiomics’ flagship product, Proprems, is a probiotic dietary supplement developed for preterm infants.
May 22, 2026

Vinge advises Sveafastigheter in its merger with KlaraBo

Vinge advises Sveafastigheter AB (publ) in its merger with KlaraBo Sverige AB.
May 22, 2026

Vinge advises Lagercrantz Group in conjunction with the acquisition of Stalon

Lagercrantz Group Aktiebolag has acquired 88 per cent of the shares in Stalon AB, a Swedish manufacturer of silencers for hunting firearms. The company is based in Stalon, which is located outside Vilhelmina, where the company conducts development and production in its own facilities.
May 21, 2026